The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
Globally, BRUKINSA is approved in more than 70 countries
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Subscribe To Our Newsletter & Stay Updated
